HLX10 + trastuzumab + chemotherapy

HLX10 + trastuzumab + chemotherapy is an investigational multi-agent regimen combining three distinct therapeutic modalities for the treatment of HER2-positive cancers, particularly advanced gastric cancer. HLX10 is a fully humanized IgG4 monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor and acts as an immune checkpoint inhibitor to enhance T-cell mediated anti-tumor responses[6][8]. Trastuzumab is a humanized monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2), inhibiting proliferation of HER2-overexpressing tumor cells[9]. The chemotherapy component typically includes agents such as XELOX (capecitabine plus oxaliplatin) or other standard regimens used in gastric cancer. This triple-combination aims to synergistically block immune evasion via PD-1 inhibition, directly target HER2-driven tumor growth with trastuzumab, and induce cytotoxicity through chemotherapy. Clinical trials are ongoing to evaluate its efficacy and safety in first-line treatment of HER2-positive locally advanced or metastatic gastric cancer[3][4].